Athersys Inc. stem cell therapy for bowel disease fails to show 'meaningful benefit' in study

Athersys Inc. of Cleveland said its MultiStem cell therapy for treating patients with a form of inflammatory bowel disease "failed to show meaningful benefit" in interim results from a Phase 2 clinical trial.

http://ift.tt/1j98A9O